Pasar al contenido principal

APLICACION TERAPEUTICA DE LA INHIBICION DE RANKL EN TUMORES SOLIDOS: PAPEL EN LAS CELULAS TUMORALES Y EN LA RESPUESTA IMMUNE TUMORAL

SAF2014-55997-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness.

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S
  • Collado-Solé, Alejandro
  • Jimenez, Maria
  • Sanz-Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C
  • De Benedictis, Ilaria
  • Gómez-Aleza, Clara
  • Da Silva-Álvarez, Sabela
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • Gonzalez-Suarez, Eva
  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S
  • Collado-Solé, Alejandro
  • Jimenez, Maria
  • Sanz-Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C
  • De Benedictis, Ilaria
  • Gómez-Aleza, Clara
  • Da Silva-Álvarez, Sabela
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • Gonzalez-Suarez, Eva
Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.
Repisalud
Publicación Artículo científico (JournalArticle)

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.

  • Ciscar, Marina
  • Trinidad, Eva M
  • Perez-Chacon, Gema
  • Alsaleem, Mansour
  • Jimenez, Maria
  • Jimenez-Santos, Maria J
  • Perez-Montoyo, Hector
  • Sanz-Moreno, Adrian
  • Vethencourt, Andrea
  • Toss, Michael
  • Petit, Anna
  • Soler-Monso, Maria T
  • Lopez, Victor
  • Gomez-Miragaya, Jorge
  • Gomez-Aleza, Clara
  • Dobrolecki, Lacey E
  • Lewis, Michael T
  • Bruna, Alejandra
  • Mouron, Silvana
  • Al-Shahrour, Fatima
  • Quintela Fandino, Miguel Angel
  • Martinez-Aranda, Antonio
  • Sierra, Angels
  • Green, Andrew R
  • Rakha, Emad
  • Gonzalez-Suarez, Eva
  • Ciscar, Marina
  • Trinidad, Eva M
  • Perez-Chacon, Gema
  • Alsaleem, Mansour
  • Jimenez, Maria
  • Jimenez-Santos, Maria J
  • Perez-Montoyo, Hector
  • Sanz-Moreno, Adrian
  • Vethencourt, Andrea
  • Toss, Michael
  • Petit, Anna
  • Soler-Monso, Maria T
  • Lopez, Victor
  • Gomez-Miragaya, Jorge
  • Gomez-Aleza, Clara
  • Dobrolecki, Lacey E
  • Lewis, Michael T
  • Bruna, Alejandra
  • Mouron, Silvana
  • Martinez-Aranda, Antonio
  • Sierra, Angels
  • Green, Andrew R
  • Rakha, Emad
  • Gonzalez-Suarez, Eva
Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor-negative, ER ) from four independent cohorts. RANK protein expression was more frequent in ER tumors, where it associated with poor outcome and poor response to chemotherapy. In ER breast cancer patient-derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK ER tumors after menopause.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G.
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S.
  • Collado-Solé, Alejandro
  • Jiménez, María
  • Sanz-Moreno, Adrián
  • Yoldi, Guillermo
  • Santos, Juliana C.
  • Benedictis, Ilaria De
  • Gómez-Aleza, Clara
  • Silva-Alvarez, S. da
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcázar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • González-Suarez, Eva
© 2021 The Authors., Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness., This work was supported by grants to E. González-Suárez by the Agencia Estatal de Investigación (AEI) (SAF2014-55997-R, SAF2017-86117-R) co-funded by FEDER funds/European Regional Development Fund (ERDF) (a way to build Europe), by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 682935), and by the Fundació La Marató de TV3. We thank CERCA Programme/Generalitat de Catalunya for institutional support. S. Benítez was a recipient of an FPI, A. Collado-Solé holds an FPU from the MICINN and J Redondo-Pedraza is a recipient of an FPI Severo Ochoa Fellowship. We are grateful to Amgen for providing Rankl and Rankt+/tg mice.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

  • Ciscar, Marina
  • Trinidad, Eva M.
  • Pérez-Chacón, Gema
  • Alsaleem, Mansour
  • Jiménez, María
  • Jiménez-Santos, María J.
  • Pérez-Montoyo, Héctor
  • Sanz-Moreno, Adrián
  • Vethencourt, Andrea
  • Toss, Michael
  • Petit, Anna
  • Soler-Monso, María T.
  • López, Victor
  • Gómez-Miragaya, Jorge
  • Gómez-Aleza, Clara
  • Dobrolecki, Lacey E.
  • Lewis, Michael T.
  • Bruna, Alejandra
  • Mouron, Silvana
  • Quintela-Fandino, Miguel
  • Al-Shahrour, Fátima
  • Martínez-Aranda, Antonio
  • Sierra, Angels
  • Green, Andrew R.
  • Rakha, Emad
  • González-Suarez, Eva
Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor‐negative, ER−) from four independent cohorts. RANK protein expression was more frequent in ER− tumors, where it associated with poor outcome and poor response to chemotherapy. In ER− breast cancer patient‐derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER− breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK+ ER− tumors after menopause., We thank Miguel Angel Pujana,Christian Tebe and Judith Pe~nafiel for the analyses of theIDBandCNIOcohorts, Sergi Velasco and Purificaci on Mu~noz for feedback about the manu-script. Work in the laboratory of EG-S has received funding from the SpanishMinisterio de Ciencia, Innovaci on y Universidades, which is part of AgenciaEstatal de Investigaci on (AEI) (SAF2014-55997-R, SAF2017-86117-R, andPID2020-116441GB-I00), the ISCIII (PIE13/00022) co-funded by EuropeanRegional Development Fund, a Career Catalyst Grant from the Susan KomenFoundation (CCR13262449), the Catalan Government2017SGR00665, co-funded by FEDER funds/European Regional Development Fund (ERDF) (a wayto build Europe), the European Research Council (ERC) under the EuropeanUnion’s Horizon2020research and innovation program (grant agreement no.682935), This study has been partially funded by Amgen Inc. EMT had receiveda Juan de la Cierva-Incorporaci on grant from Spanish Ministry of Science andInnovation (IJCI-2017-31564) and MG a PERIS contract from the Departamentof Salut de la Generalitat de Catalunya. The IDIBELL samples collection wasgranted by the Spanish Ministry of Health and Consumer Affairs FIS-PI14/00336from the I+D+I National Plan with the financial support from ISCIII-Subdirecci on General de Evaluaci on and the Fondo Europeo de DesarrolloRegional (FEDER). The generation of PDX models in the Lewis laboratory wassupported in part by NIH/NCI grants U54CA224076(MTL), U24CA226110(toMTL), P50CA186784(MTL) (Dan L. Duncan Cancer Center). This work was alsosupported by a Core Facility grant from the Cancer Prevention and ResearchInstitute of Texas (CPRIT Core Facilities Support Grant RP170691), Peer reviewed